These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 22102553)

  • 1. Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia.
    Rabin KR; Gramatges MM; Borowitz MJ; Palla SL; Shi X; Margolin JF; Zweidler-McKay PA
    Pediatr Blood Cancer; 2012 Sep; 59(3):468-74. PubMed ID: 22102553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of absolute lymphocyte counts at the end of remission induction in childhood acute lymphoblastic leukemia.
    Rubnitz JE; Campbell P; Zhou Y; Sandlund JT; Jeha S; Ribeiro RC; Inaba H; Bhojwani D; Relling MV; Howard SC; Campana D; Pui CH
    Cancer; 2013 Jun; 119(11):2061-6. PubMed ID: 23456849
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absolute Lymphocyte Count (ALC) after Induction Treatment Predicts Survival of Pediatric Patients with Acute Lymphoblastic Leukemia.
    Farkas T; Müller J; Erdelyi DJ; Csoka M; Kovacs GT
    Pathol Oncol Res; 2017 Oct; 23(4):889-897. PubMed ID: 28138921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Absolute Lymphocyte Count Recovery Independently Predicts Outcome in Childhood Acute Lymphoblastic Leukemia: Experience From a Tertiary Care Cancer Center of a Developing Country.
    Gupta A; Kapoor G; Jain S; Bajpai R
    J Pediatr Hematol Oncol; 2015 Apr; 37(3):e143-9. PubMed ID: 26201035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Absolute lymphocyte count is a novel prognostic indicator in ALL and AML: implications for risk stratification and future studies.
    De Angulo G; Yuen C; Palla SL; Anderson PM; Zweidler-McKay PA
    Cancer; 2008 Jan; 112(2):407-15. PubMed ID: 18058809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Multicenter evaluation of minimal residual disease monitoring in early induction therapy for treatment of childhood acute lymphoblastic leukemia].
    Wu XJ; Liao N; Mai HR; Li XY; Wan WQ; Yang LH; Huang LB; Luo XQ; Tian C; Chen QW; Long XJ; He YY; Wang Y; Li ZG; Xu HG
    Zhonghua Er Ke Za Zhi; 2024 Mar; 62(4):337-344. PubMed ID: 38527504
    [No Abstract]   [Full Text] [Related]  

  • 7. Association of absolute lymphocyte count and peripheral blood lymphocyte subsets percentage with minimal residual disease at the end of induction in pediatric B cell acute lymphoblastic leukemia.
    Pushpam D; Rajput N; Chopra A; Vishnubhatla S; Kumari M; Kumar R; Bakhshi S
    Pediatr Hematol Oncol; 2019 Apr; 36(3):138-150. PubMed ID: 31046540
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Absolute lymphocyte count at the end of induction therapy is a prognostic factor in childhood acute lymphoblastic leukemia.
    Hirase S; Hasegawa D; Takahashi H; Moriwaki K; Saito A; Kozaki A; Ishida T; Yanai T; Kawasaki K; Yamamoto N; Kubokawa I; Mori T; Hayakawa A; Nishimura N; Nishio H; Iijima K; Kosaka Y
    Int J Hematol; 2015 Nov; 102(5):594-601. PubMed ID: 26440971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The ratio of absolute lymphocyte count at interim of therapy to absolute lymphocyte count at diagnosis predicts survival in childhood B-lineage acute lymphoblastic leukemia.
    Cheng Y; Luo Z; Yang S; Jia M; Zhao H; Xu W; Tang Y
    Leuk Res; 2015 Feb; 39(2):144-50. PubMed ID: 25542697
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low absolute neutrophil count during induction therapy is an adverse prognostic factor in childhood acute lymphoblastic leukaemia.
    Chen X; Liu C; Zhang A; Wu W; Liu L; Lan Y; Yi M; Zhang L; Ruan M; Chang L; Zhang L; Zou Y; Chen Y; Yang W; Guo Y; Chen X; Zhang Y; Zhu X
    Ann Hematol; 2021 Sep; 100(9):2269-2277. PubMed ID: 33443592
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absolute lymphocyte count is associated with minimal residual disease level in childhood B-cell precursor acute lymphoblastic leukemia.
    Shen HQ; Feng JH; Tang YM; Song H; Yang SL; Shi SW; Xu WQ
    Leuk Res; 2013 Jun; 37(6):671-4. PubMed ID: 23453285
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Monitoring of minimal residual disease in children with acute lymphoblastic leukemia and its prognostic significance].
    Xu XJ; Tang YM; Song H; Shi SW; Yang SL; Shen HQ; Wei J; Xu WQ; Pan BH; Zhao FY
    Zhonghua Er Ke Za Zhi; 2010 Mar; 48(3):180-4. PubMed ID: 20426951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].
    Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X
    Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of MRD-dynamics in childhood acute lymphoblastic leukemia treated according to the MB-2002/2008 protocols.
    Meleshko AN; Savva NN; Fedasenka UU; Romancova AS; Krasko OV; Eckert C; von Stackelberg A; Aleinikova OV
    Leuk Res; 2011 Oct; 35(10):1312-20. PubMed ID: 21596436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prognostic significance and risk factors of minimal residual disease ≥1% on 19th day of induction chemotherapy in children with acute lymphoblastic leukemia].
    Yu J; Yi T; Lin G; Wen J; Chen L; Chen J; Wu X
    Nan Fang Yi Ke Da Xue Xue Bao; 2020 Feb; 40(2):255-261. PubMed ID: 32376526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absolute lymphocyte count at day 28 independently predicts event-free and overall survival in adults with newly diagnosed acute lymphoblastic leukemia.
    Sun D; Elson P; Liedtke M; Medeiros BC; Earl M; Alizadeh A; Bates J; Sekeres MA; Coutre S; Kalaycio M; Sobecks R; Copelan E; Advani AS
    Am J Hematol; 2012 Oct; 87(10):957-60. PubMed ID: 22729847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Absolute Lymphocyte Count at the End of Induction as a Surrogate Marker for Minimal Residual Disease in T-cell Acute Lymphoblastic Leukemia.
    Pushpam D; Chopra A; Sreenivas V; Kumar R; Bakhshi S
    Indian Pediatr; 2019 May; 56(5):381-383. PubMed ID: 30898988
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment reduction for children and young adults with low-risk acute lymphoblastic leukaemia defined by minimal residual disease (UKALL 2003): a randomised controlled trial.
    Vora A; Goulden N; Wade R; Mitchell C; Hancock J; Hough R; Rowntree C; Richards S
    Lancet Oncol; 2013 Mar; 14(3):199-209. PubMed ID: 23395119
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
    Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
    Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value.
    Vidriales MB; Pérez JJ; López-Berges MC; Gutiérrez N; Ciudad J; Lucio P; Vazquez L; García-Sanz R; del Cañizo MC; Fernández-Calvo J; Ramos F; Rodríguez MJ; Calmuntia MJ; Porwith A; Orfao A; San-Miguel JF
    Blood; 2003 Jun; 101(12):4695-700. PubMed ID: 12586618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.